Public Page
NeuroXense
NeuroXense is building an infrastructure for neurodegenerative disease detection: a proprietary aptamer-based platform for early, non-invasive diagnosis, initially targeting Parkinson’s disease using tear fluid. The business model is B2B2B. NeuroXense is raising a USD 200–250k Pre-Seed round to achieve a functional aptamer MVP in the lab, file a provisional patent, and secure 3 signed LOIs.
Healthtech / HealthcarePre-seedArgentina
Interested in NeuroXense?
Request access to the full data room to review financials, documents and due diligence materials.